Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799814 | 1.00 | CYP3A4 (0.38) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL12769438 | 1.00 | CYP3A4 (0.38) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL12784431 | 0.93 | CYP3A4 (0.35) | CYP3A4CTSBPPP3CBHDAC1 | |
| SCHEMBL11984006 | 0.92 | CYP3A4 (0.37) | CYP3A4HDAC8HDAC1 | |
| SCHEMBL7939394 | 0.90 | HDAC1 (0.40) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL3470046 | 0.89 | CYP3A4 (0.37) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL12768163 | 0.89 | CYP3A4 (0.37) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL3470049 | 0.89 | CYP3A4 (0.37) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL3805728 | 0.87 | CYP3A4 (0.36) | CYP3A4CTSBPPP3CBHDAC8HDAC1 | |
| SCHEMBL3805730 | 0.87 | CYP3A4 (0.36) | CYP3A4CTSBPPP3CBHDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CYP3A4 826/4885CTSB 550/4885PPP3CB 1215/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CYP3A4 826/4885CTSB 550/4885PPP3CB 1215/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CYP3A4 826/4885CTSB 550/4885PPP3CB 1215/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | CYP3A4 755/4885CTSB 541/4885PPP3CB 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.